XC8

Phase 2Small molecule

CChemlmmune Therapeutics LLC

XC8 is one of 21 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaActive, not recruiting

AsthmaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Cinqair

Teva

Preclinical

13 2

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 3

Spiriva

Boehringer Ingelheim

Preclinical

8 4

Formoterol Fumarate

AstraZeneca

Preclinical

8 5

Atrovent

Boehringer Ingelheim

Preclinical

2 6

Aciphex

Akero Therapeutics

Preclinical

2 7

XC8

CChemlmmune Therapeutics LLC

Phase 2

2 8

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 9

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 10

Ozone

TTanta University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics3 trials

Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers

Completed·VValenta Pharm JSC·N/A·NCT05558462·24 enrolled

XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers

Completed·PPHARMENTERPRISES LLC·Phase 1·NCT03441815·28 enrolled

Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8

Completed·EEURRUS Biotech GmbH·Phase 1·NCT02882217·32 enrolled

Asthma2 trials

XC8 in the Treatment of Patients With the Eosinophilic Phenotype of Bronchial Asthma

Completed·CChemlmmune Therapeutics LLC·Phase 2·NCT04674137·70 enrolled

XC8 in the Treatment of Patients With Bronchial Asthma

Completed·PPHARMENTERPRISES LLC·Phase 2·NCT03450434·120 enrolled

Acute Respiratory Viral Infections1 trial

Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections

Recruiting·VValenta Pharm JSC·Phase 3·NCT06379542·252 enrolled

Respiratory Viral Infection1 trial

XC8 in the Treatment of Patients With Acute Respiratory Viral Infection

Completed·PPHARMENTERPRISES LLC·Phase 2/3·NCT03441373·320 enrolled

TED1 trial

Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets

Completed·VValenta Pharm JSC·Phase 1·NCT05294250·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for XC8. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — XC8 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for XC8. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Chemlmmune Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CChemlmmune Therapeutics LLC

XC8

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics3 trials

Asthma2 trials

Acute Respiratory Viral Infections1 trial

Respiratory Viral Infection1 trial

TED1 trial

References

Drug Info

Quick Facts

Related News